The business income of multinational pharmaceutical companies in China market surfaced, with Merck and AstraZeneca both exceeding $5.8 billion.

　　【Industry trends of pharmaceutical networkBased on the huge market demand in China and the continuous optimization of the policy environment, many foreign pharmaceutical companies have actively increased the layout of the China market and achieved good results. With the global pharmaceutical companies disclosing their 2023 financial reports one after another, their business income in China market also surfaced.
　

　　According to combing, in 2023, Merck’s business income in China reached 6.71 billion US dollars; AstraZeneca’s business income in China reached $5.876 billion; The business revenues of Novartis, Sanofi, Roche, Novo Nordisk and Lilly in China were US$ 3.267 billion, US$ 3.184 billion, US$ 3.171 billion, US$ 2.42 billion and US$ 1.54 billion respectively.
　

　　According to the 2023 financial report released by Merck, the company’s global sales in 2023 were US$ 60.1 billion, a year-on-year increase of 1%; The net profit of returning to the mother was $365 million, a year-on-year decrease of 97.49%. Among them, Merck’s revenue in China in 2023 was USD 6.71 billion, accounting for 12.5% of the company’s global market, with a year-on-year increase of 32%.
　

　　According to the industry, Merck has successfully seized the growth opportunity of China market by continuously introducing new original drug products and cooperating with local companies. In 2023, Merck’s layout and strategy in China market received positive feedback and became a multinational pharmaceutical company with good performance in China in 2023.
　

　　According to AstraZeneca’s 2023 results, the company’s total revenue in 2023 was 45.811 billion US dollars (+3%), of which product revenue was 43.789 billion US dollars, up 2% year-on-year. After deducting COVID-19’s products, the total revenue was US$ 45.488 billion, up 13% year-on-year. In terms of regional distribution, the annual income of the US market was US$ 19.077 billion, a year-on-year increase of 6%. Emerging markets reached US$ 12.025 billion, a year-on-year increase of 2%. Among them, China contributed US$ 5.876 billion, accounting for 13% of AstraZeneca’s global market.
　

　　It is understood that since the beginning of this year, AstraZeneca has also continuously increased its production and R&D layout in China. For example, in early March, AstraZeneca and Wuxi officially signed a cooperation agreement on a new small molecule innovative drug factory project with a total investment of 475 million US dollars, which will realize the production of specific small molecule drugs from preparation to packaging in Wuxi, and strive to build AstraZeneca into one of the global production and supply bases in China.
　

　　AstraZeneca recently announced that Shanghai has become its fifth largest global strategic center. Shanghai, China will become a global strategic center integrating R&D, commerce, production and operation in addition to the four R&D-oriented strategic centers in Cambridge, Boston, gaithersburg and Gothenburg, Sweden, and become an important strategic fulcrum for AstraZeneca’s global strategy, R&D and long-term development.
　

　　According to the 2023 financial report released by Novartis, the company’s annual revenue in 2023 was 45.44 billion US dollars, a year-on-year increase of 10%; Net profit was $8.572 billion, up 62% year-on-year. In 2023, Novartis achieved an operating income of $3.3 billion in China, a year-on-year increase of 17%. It is reported that in terms of production capacity, Novartis announced on December 1, 2023 that it plans to invest more than 600 million yuan to set up a radiopharmaceutical production base in Haiyan, Zhejiang, in order to accelerate the pace of introducing innovative radioligand therapy into China.
　

　　According to the 2023 financial report released by Sanofi, the company’s sales in 2023 reached 43.07 billion euros (46.52 billion dollars, converted at the current exchange rate of 1 euro =1.08 dollars, the same below), a year-on-year increase of 5.3%. From the geographical distribution of income, the US market is still the main battlefield of Sanofi, contributing 18.512 billion euros (about 20.243 billion US dollars) in revenue, up 4.8% year-on-year; China’s market revenue was 2.912 billion euros (about 3.184 billion US dollars), and its growth rate also slowed down (0.4% in 2023 and 6.2% in the same period last year).
　

　　It is reported that in 2023, Sanofi was approved for 12 innovative products and indications in the China market. Earlier, it announced that it planned to introduce 25 innovative products and indications in China from 2020 to 2025. With the approval of Le Weichu, the first respiratory syncytial virus prevention method for all infants at the end of 2023, Sanofi announced that it would achieve its goal two years ahead of schedule.
　

　　In addition, Roche achieved a total revenue of US$ 65.627 billion in 2023, including China business income of US$ 3.171 billion, an increase of 6%. In 2023, Novo Nordisk’s revenue reached about 33.771 billion US dollars, a year-on-year increase of 31%; The company’s operating profit also increased by 37%, reaching about $14.914 billion, of which China’s business income was $2.42 billion, an increase of 11%. Lilly achieved revenue of $34.124 billion in 2023, up 20% year-on-year, net profit of $5.24 billion, down 16% year-on-year, and revenue of China District was $1.540 billion, up 11% year-on-year.
　

　　Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone.